Deep response in multiple myeloma: a critical review.
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Novel and more effective treatment strategies against multiple myeloma (MM) have significantly prolonged patients’ survival and raised interest in the depth of response and its association with clinical outcome. Minimal residual disease (MRD) has emerged as one of the most relevant prognostic factors in MM and should be included in a new definition of complete response (CR). Although further standardization is still required, MRD monitoring should be applied in prospective clinical trials as a sensitive tool to compare and evaluate the efficacy of different treatment strategies, particularly in the consolidation and maintenance settings, and implement individualized therapy-monitoring approaches. Here, we review current definition of deep response in MM, advantages and limitations of current MRD assessment assays, clinical evidences for MRD monitoring as a prognostic tool for therapeutic decisions in MM, and challenges to develop uniform criteria for MRD monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632 · cited 1×
“The International Myeloma Working Group (IMWG) in 2006 has introduced normalization of sFLCs and absence of clonal PCs in BM biopsies by immunohistochemistry and/or immunofluorescence as additional requirements to define more stringent CR criteria [10].”
MethodBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Initial genome sequencing and analysis of multiple myeloma
Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C., Schinzel, A. C., Harview, C. L., Brunet, J.-P., Ahmann, G. J., Adli, M., et al. (2011) · Nature · doi:10.1038/nature09837 · Cited by 1,433
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationClinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
The genetic architecture of multiple myeloma
Morgan, G. J., Walker, B. A., & Davies, F. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3257 · Cited by 913
Zamagni, E., Patriarca, F., Nanni, C., Zannetti, B., Englaro, E., Pezzi, A., Tacchetti, P., Buttignol, S., Perrone, G., Brioli, A., et al. (2011) · Blood · doi:10.1182/blood-2011-06-361386 · Cited by 531
Rosiñol, L., Oriol, A., Teruel, A. I., Hernández, D., López-Jiménez, J., de la Rubia, J., Granell, M., Besalduch, J., Palomera, L., González, Y., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408922 · Cited by 486
Barlogie, B., Shaughnessy, J., Tricot, G., Jacobson, J., Zangari, M., Anaissie, E., Walker, R., & Crowley, J. (2004) · Blood · doi:10.1182/blood-2003-04-1045 · Cited by 464
Martinez-Lopez, J., Lahuerta, J. J., Pepin, F., González, M., Barrio, S., Ayala, R., Puig, N., Montalban, M. A., Paiva, B., Weng, L., et al. (2014) · Blood · doi:10.1182/blood-2014-01-550020 · Cited by 425
Rawstron, A. C., Child, J. A., de Tute, R. M., Davies, F. E., Gregory, W. M., Bell, S. E., Szubert, A. J., Navarro-Coy, N., Drayson, M. T., Feyler, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2119 · Cited by 415
Cavo, M., Rajkumar, S. V., Palumbo, A., Moreau, P., Orlowski, R., Bladé, J., Sezer, O., Ludwig, H., Dimopoulos, M. A., Attal, M., et al. (2011) · Blood · doi:10.1182/blood-2011-02-297325 · Cited by 314
Ladetto, M., Brüggemann, M., Monitillo, L., Ferrero, S., Pepin, F., Drandi, D., Barbero, D., Palumbo, A., Passera, R., Boccadoro, M., et al. (2014) · Leukemia · doi:10.1038/leu.2013.375 · Cited by 304
Paiva, B., Gutiérrez, N. C., Rosiñol, L., Vídriales, M.-B., Montalbán, M.-Á., Martínez-López, J., Mateos, M.-V., Cibeira, M.-T., Cordón, L., Oriol, A., et al. (2012) · Blood · doi:10.1182/blood-2011-07-370460 · Cited by 300
New criteria for response assessment: role of minimal residual disease in multiple myeloma
Paiva, B., van Dongen, J. J. M., & Orfao, A. (2015) · Blood · doi:10.1182/blood-2014-11-568907 · Cited by 299
Ladetto, M., Pagliano, G., Ferrero, S., Cavallo, F., Drandi, D., Santo, L., Crippa, C., De Rosa, L., Pregno, P., Grasso, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7172 · Cited by 267
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6180 · Cited by 265
Gay, F., Larocca, A., Wijermans, P., Cavallo, F., Rossi, D., Schaafsma, R., Genuardi, M., Romano, A., Liberati, A. M., Siniscalchi, A., et al. (2011) · Blood · doi:10.1182/blood-2010-09-307645 · Cited by 263
Curing myeloma at last: defining criteria and providing the evidence
Barlogie, B., Mitchell, A., van Rhee, F., Epstein, J., Morgan, G. J., & Crowley, J. (2014) · Blood · doi:10.1182/blood-2014-07-552059 · Cited by 235
Paiva, B., Martinez-Lopez, J., Vidriales, M.-B., Mateos, M.-V., Montalban, M.-A., Fernandez-Redondo, E., Alonso, L., Oriol, A., Teruel, A.-I., de Paz, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.1967 · Cited by 233
III. On a new substance occurring in the urine of a patient with mollities ossium
Jones, H. B. (1848) · Philosophical Transactions of the Royal Society of London · doi:10.1098/rstl.1848.0003 · Cited by 218
Roadmap for Harmonization of Clinical Laboratory Measurement Procedures
Greg Miller, W., Myers, G. L., Lou Gantzer, M., Kahn, S. E., Schönbrunner, E. R., Thienpont, L. M., Bunk, D. M., Christenson, R. H., Eckfeldt, J. H., Lo, S. F., et al. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.164012 · Cited by 213
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation
Martinez-Lopez, J., Blade, J., Mateos, M.-V., Grande, C., Alegre, A., García-Laraña, J., Sureda, A., de la Rubia, J., Conde, E., Martinez, R., et al. (2011) · Blood · doi:10.1182/blood-2011-01-332320 · Cited by 206
Paiva, B., Almeida, J., Pérez‐Andrés, M., Mateo, G., López, A., Rasillo, A., Vídriales, M., López‐Berges, M., Miguel, J. F. S., & Orfao, A. (2010) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.20512 · Cited by 203
Usmani, S. Z., Mitchell, A., Waheed, S., Crowley, J., Hoering, A., Petty, N., Brown, T., Bartel, T., Anaissie, E., van Rhee, F., et al. (2013) · Blood · doi:10.1182/blood-2012-08-451690 · Cited by 201
van Rhee, F., Bolejack, V., Hollmig, K., Pineda-Roman, M., Anaissie, E., Epstein, J., Shaughnessy, J. D., Zangari, M., Tricot, G., Mohiuddin, A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-067728 · Cited by 184
Rawstron, A. C., Gregory, W. M., de Tute, R. M., Davies, F. E., Bell, S. E., Drayson, M. T., Cook, G., Jackson, G. H., Morgan, G. J., Child, J. A., et al. (2015) · Blood · doi:10.1182/blood-2014-07-590166 · Cited by 178
Paiva, B., Paino, T., Sayagues, J.-M., Garayoa, M., San-Segundo, L., Martín, M., Mota, I., Sanchez, M.-L., Bárcena, P., Aires-Mejia, I., et al. (2013) · Blood · doi:10.1182/blood-2013-06-510453 · Cited by 173
Puig, N., Sarasquete, M. E., Balanzategui, A., Martínez, J., Paiva, B., García, H., Fumero, S., Jiménez, C., Alcoceba, M., Chillón, M. C., et al. (2014) · Leukemia · doi:10.1038/leu.2013.217 · Cited by 170
Kapoor, P., Kumar, S. K., Dispenzieri, A., Lacy, M. Q., Buadi, F., Dingli, D., Russell, S. J., Hayman, S. R., Witzig, T. E., Lust, J. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.0086 · Cited by 162
Kantarjian, H., Schiffer, C., Jones, D., & Cortes, J. (2008) · Blood · doi:10.1182/blood-2007-09-110189 · Cited by 158
Has MRD monitoring superseded other prognostic factors in adult ALL?
Brüggemann, M., Raff, T., & Kneba, M. (2012) · Blood · doi:10.1182/blood-2012-06-379040 · Cited by 151
Kalina, T., Flores-Montero, J. A., Lécrevisse, Q., Pedreira, C. E., van der Velden, V. H. J., Nováková, M., Mejstříková, E., Hrušák, O., Böttcher, S., Karsch, D., et al. (2014) · Cytometry Part A · doi:10.1002/cyto.a.22581 · Cited by 145
Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma
Kyrtsonis, M., Vassilakopoulos, T. P., Kafasi, N., Sachanas, S., Tzenou, T., Papadogiannis, A., Galanis, Z., Kalpadakis, C., Dimou, M., Kyriakou, E., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06561.x · Cited by 129
Ludwig, H., Milosavljevic, D., Zojer, N., Faint, J., Bradwell, A. R., Hübl, W., & Harding, S. J. (2012) · Leukemia · doi:10.1038/leu.2012.197 · Cited by 127
Zent, C. S., Wilson, C. S., Tricot, G. J. K., Jagannath, S., Siegel, D. S. D., Desikan, K. R., Munshi, N. C., Bracy, D., Barlogie, B., & Butch, A. W. (1998) · Blood · doi:10.1182/blood.v91.9.3518 · Cited by 126
Self-citationDavies, F. E., Forsyth, P. D., Rawstron, A. C., Owen, R. G., Pratt, G., Evans, P. A. S., Richards, S. J., Drayson, M., Smith, G. M., Selby, P. J., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02530.x · Cited by 110
Cavo, M., Terragna, C., Martinelli, G., Ronconi, S., Zamagni, E., Tosi, P., Lemoli, R. M., Benni, M., Pagliani, G., Bandini, G., et al. (2000) · Blood · doi:10.1182/blood.v96.1.355 · Cited by 100
Martínez‐López, J., Paiva, B., López‐Anglada, L., Mateos, M., Cedena, M., Vídriales, M., Sáez-Gómez, M. A., Contreras, T., Oriol, A., Rapado, I., et al. (2015) · Blood · doi:10.1182/blood-2015-04-638742 · Cited by 90
Ferrero, S., Ladetto, M., Drandi, D., Cavallo, F., Genuardi, E., Urbano, M. A., Caltagirone, S., Grasso, M., Rossini, F., Guglielmelli, T., et al. (2014) · Leukemia · doi:10.1038/leu.2014.219 · Cited by 85
Assessment of minimal residual disease in acute myeloid leukemia
Grimwade, D. J., Vyas, P., & Freeman, S. D. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833ed831 · Cited by 81
Clonogenic Multiple Myeloma Cells have Shared stemness Signature Associated with Patient Survival
Reghunathan, R., Bi, C., Liu, S. C., Koh, T.-L., Chung, T., Huang, G., & Chng, W. J. (2013) · Oncotarget · doi:10.18632/oncotarget.1145 · Cited by 72
Galimberti, S., Benedetti, E., Morabito, F., Papineschi, F., Callea, V., Fazzi, R., Stelitano, C. C., Andreazzoli, F., Guerrini, F., Ciabatti, E., et al. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.01.017 · Cited by 57
White, H., Hedges, J. B., Bendit, I., Branford, S., Colomer, D., Hochhaus, A., Hughes, T. P., Kamel‐Reid, S., Kim, D., Modur, V., et al. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.196477 · Cited by 54
Paiva, B., Chandia, M., Puig, N., Vidriales, M.-B., Perez, J. J., Lopez-Corral, L., Ocio, E. M., Garcia-Sanz, R., Gutierrez, N. C., Jimenez-Ubieto, A., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.115162 · Cited by 53
Chee, C. E., Kumar, S., Larson, D. R., Kyle, R. A., Dispenzieri, A., Gertz, M. A., Colby, C. L., & Rajkumar, S. V. (2009) · Blood · doi:10.1182/blood-2009-01-198788 · Cited by 51
Singhal, S., Vickrey, E., Krishnamurthy, J., Singh, V., Allen, S., & Mehta, J. (2009) · Blood · doi:10.1182/blood-2009-02-205807 · Cited by 46
Martínez‐López, J., Fernández‐Redondo, E., García‐Sánz, R., Montalbán, M.-Á., Martínez‐Sánchez, P., Pavia, B., Mateos, M., Rosiñol, L., Martín, M., Ayala, R. M., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12576 · Cited by 35
Giarin, M. M., Giaccone, L., Sorasio, R., Sfiligoi, C., Amoroso, B., Cavallo, F., Cipriani, A., Palumbo, A., & Boccadoro, M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.124370 · Cited by 33
Harmonisation of laboratory testing.
Tate, J. R., Johnson, R. N., & Legg, M. (2012) · Europe PMC (PubMed Central) · Cited by 30
Sensitivity of serum free light chain measurement of residual disease in multiple myeloma patients
Mead, G. P., & Drayson, M. T. (2009) · Blood · doi:10.1182/blood-2009-06-225854 · Cited by 14
The utility of newer imaging techniques as predictors of clinical outcomes in multiple myeloma
Brioli, A., Morgan, G. J., Durie, B. G. M., & Zamagni, E. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.873347 · Cited by 12
de Larrea, C. F., Tovar, N., Rozman, M., Rosiñol, L., Aróstegui, J. I., Cibeira, M. T., Rovira, M., Yagüe, J., & Bladé, J. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.12.707 · Cited by 8
Research works printed but not linked: 1
- Ludwig H. Slavka G. Hubl W. Usage of HLC-ratio, FLC-ratio, Ife, PBMC infiltration and isotype suppression at best response reveals isotype suppression as most powerful parameter for identification of multiple myeloma patients with long survival ASH Annual Meeting Abstracts 1817 120 21 p. 1817
Cited by
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Self-citationFlores-Montero, J., Sanoja-Flores, L., Paiva, B., Puig, N., García-Sánchez, O., Böttcher, S., van der Velden, V. H. J., Pérez-Morán, J.-J., Vidriales, M.-B., García-Sanz, R., et al. (2017) · Leukemia · doi:10.1038/leu.2017.29 · Cited by 676
Prognostic and predictive biomarker developments in multiple myeloma
Wallington-Beddoe, C. T., & Mynott, R. L. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01162-7 · Cited by 172
Oberle, A., Brandt, A. P., Voigtlaender, M., Thiele, B., Radloff, J., Schulenkorf, A., Alawi, M., Akyüz, N., März, M., Ford, C. T., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.161414 · Cited by 115
Avet‐Loiseau, H., Miguel, J. F. S., Casneuf, T., Iida, S., Lonial, S., Usmani, S. Z., Spencer, A. G., Moreau, P., Plesner, T., Weisel, K. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01814 · Cited by 103
Metadata
- Authors
- Fulciniti, M., Munshi, N. C., & Martinez-Lopez, J.
- Affiliations
- Harvard University (US)
- Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
- Corresponding author
- Fulciniti, Mariateresa
- Venue
- BioMed Research International
- Publisher
- Hindawi Limited
- Published
- 2015
- Volume
- 2015
- Pages
- 1-7
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- PMC
- PMC4689894
- OpenAlex
- W2191437528
- Cited by
- 40
- References
- 54
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 11 · 2020: 6 · 2019: 4 · 2018: 1 · 2017: 10 · 2016: 2
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- BioMed Research International (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, minimal residual disease, deep response, complete response, MRD monitoring, prognostic factors, consolidation therapy, maintenance therapy, treatment response criteria
- MeSH terms
- Humans, Multiple Myeloma, Prognosis, Remission Induction, Treatment Outcome, Neoplasm, Residual
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.